Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;4(3):303-6.
doi: 10.3980/j.issn.2222-3959.2011.03.19. Epub 2011 Jun 18.

Application of Lutein and Zeaxanthin in nonproliferative diabetic retinopathy

Affiliations

Application of Lutein and Zeaxanthin in nonproliferative diabetic retinopathy

Bo-Jie Hu et al. Int J Ophthalmol. 2011.

Abstract

Aim: To compare serum Lutein and Zeaxanthin (L/Z) concentrations between patients with nonproliferative diabetic retinopathy (NDR) and normal subjects, and to explore the effect of L/Z supplementation on serum L/Z level and visual function in NDR patients

Methods: SUBJECTS WERE DIVIDED INTO THREE GROUPS: 30 NDR patients supplied with Lutein 6mg/d and Zeaxanthin 0.5mg/d for three months (DR Group), 30 NDR patients without L/Z supplementation (DR Control Group) and 30 normal subjects (Control Group). Serum L/Z concentrations were measured by liquid high-resolution chromatography (HPLC). Visual acuity was recorded at baseline, 1 month, 2 months and 3 months post initial supplementation. Serum L/Z concentration were measured at baseline, 1 month and 2 months post initial supplementation. Contrast sensitivity (CS) and fovea thickness were recorded at baseline and 3 months post initial supplementation.

Results: Mean serum lutein concentrations in DR group were 0.0686±0.0296µg/mL and zeaxanthin concentration was 0.0137±0.0059µg/mL. The L/Z level of DR group was significantly lower compared to the control group (lutein: 0.2302±0.1308µg/mL, zeaxanthin: 0.0456±0.0266µg/m, P=0.000). The concentration of lutein and zeaxanthin in the DR control group at base line was 0.0714±0.0357µg/mL and 0.0119±0.0072µg/mL, respectively. There was no significant change of L/Z concentration in the DR control group during the study. Serum L/Z concentrations of DR group increased significantly after supplementation (F=109.124, P=0.000; F=219.207, P=0.000). Visual acuity improved significantly after medication. Compared with pre-medication, the average CS values of 1.5cpd, 3cpd and 6cpd after three months increased significantly (P=0.030,0.013,0.008) and the foveal thickness decreased. (P=0.05)

Conclusion: Serum L/Z concentrations in DR patients are significantly lower than those in normal subjects, and L/Z intake can improve the visual acuity, CS and macular edema in DR patients, suggesting that L/Z supplementation might be targeted as potential potential therapeutic agents in treating NDR.

Keywords: Lutein; Zeaxanthin; contrast sensitivity; liquid high-resolution chromatography; nonproliferative diabetic retinopathy; optical coherence tomography; visual acuity.

PubMed Disclaimer

References

    1. Harikumar KB, Nimita CV, Preethi KC, Kuttan R, Shankaranarayana ML, Deshpande J. Toxicity profile of lutein and lutein ester isolated from marigold flowers (Tagetes erecta) Int J Toxicol. 2008;27:1–9. - PubMed
    1. Krinsky NI, Landrum JT, Bone RA. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Ann Rev Nutr. 2003;23:171–201. - PubMed
    1. Hammond BR, Jr, FRICKJ E. Nutritional protection of the developing retina. The Hong Kong Practitioner. 2007;29:128.
    1. Bone R A, Landrum JT, Fernandez L, Tarsis SL. Analysis of the macular pigment by HPLC: retinal distribution and age study. Invest Ophthalmol Vis Sci. 1988;29:843–849. - PubMed
    1. Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, Bressler NM. Detection of diabetic foveal edema:contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol. 2004;122(3):330–335. - PubMed

LinkOut - more resources